Montag A & Associates Inc. Sells 3,407 Shares of Johnson & Johnson $JNJ

Montag A & Associates Inc. lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 3.9% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 84,820 shares of the company’s stock after selling 3,407 shares during the quarter. Montag A & Associates Inc.’s holdings in Johnson & Johnson were worth $15,727,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of Johnson & Johnson during the second quarter worth $4,877,174,000. Laurel Wealth Advisors LLC raised its stake in shares of Johnson & Johnson by 15,040.6% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company’s stock valued at $1,133,512,000 after purchasing an additional 7,371,687 shares during the period. Vanguard Group Inc. boosted its stake in Johnson & Johnson by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock worth $36,209,060,000 after purchasing an additional 3,085,180 shares during the period. Geode Capital Management LLC grew its holdings in Johnson & Johnson by 2.1% during the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after buying an additional 1,225,676 shares in the last quarter. Finally, Legal & General Group Plc increased its position in shares of Johnson & Johnson by 6.2% during the second quarter. Legal & General Group Plc now owns 18,917,274 shares of the company’s stock valued at $2,889,614,000 after buying an additional 1,097,855 shares during the period. 69.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on JNJ shares. Scotiabank restated an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Stifel Nicolaus raised their price target on shares of Johnson & Johnson from $205.00 to $220.00 and gave the company a “hold” rating in a report on Thursday, January 22nd. Morgan Stanley set a $262.00 price target on shares of Johnson & Johnson and gave the company an “overweight” rating in a research report on Wednesday, January 28th. The Goldman Sachs Group reiterated a “buy” rating and issued a $250.00 price objective on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Finally, Daiwa Securities Group boosted their target price on Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a research report on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $232.70.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA Fast Track for nipocalimab in systemic lupus erythematosus (SLE) — designation follows positive Phase 2 data and a Phase 3 enrollment; this can speed review and raises the commercial potential of a new immunology asset. PR Newswire
• Positive Sentiment: Drug pipeline momentum: J&J reported encouraging early results for oncology candidate pasritamig and is preparing Phase 3 plans; continued progress across immunology and neuroscience (Tremfya, Caplyta, Spravato) is offsetting some revenue headwinds. Yahoo Finance
• Positive Sentiment: Market context: broader Dow strength is supporting JNJ’s move higher today as large-cap pharma recovers, giving momentum to shares. Kalkine Media
• Neutral Sentiment: Investor events and cadence: J&J scheduled an investor conference call for April 14 to review Q1 results — a routine event that could provide guidance/clarity but is not immediate catalyst. Business Wire
• Neutral Sentiment: Income appeal: J&J appears on several March dividend-stock lists, reinforcing steady-income investor interest but offering limited short-term price impact. Blockonomi
• Neutral Sentiment: Conference presentation material (TD Cowen transcript) gives investors detail on strategy and pipeline execution; useful for longer-term thesis but not an immediate mover. Seeking Alpha
• Negative Sentiment: Bayer legal action: Bayer has initiated a legal challenge related to prostate-cancer product claims — this creates regulatory and litigation risk that could weigh on sentiment and add to uncertainty. Yahoo Finance
• Negative Sentiment: Analyst stance: some sell-side notes (Bank of America reiteration/Hold) point to limited near-term upside despite better oncology estimates — tempers rally expectations. TipRanks

Johnson & Johnson Stock Down 0.7%

Shares of NYSE:JNJ opened at $246.77 on Wednesday. The firm has a market capitalization of $594.69 billion, a PE ratio of 22.33, a price-to-earnings-growth ratio of 2.41 and a beta of 0.34. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $251.71. The firm has a fifty day moving average of $226.32 and a 200 day moving average of $203.01.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The firm had revenue of $24.28 billion during the quarter. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio is currently 47.06%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the transaction, the executive vice president directly owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 30,142 shares of company stock worth $7,360,528 over the last quarter. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.